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Use of prescribed contraception in Northern Ireland 2010-2016 
Abstract  
Objective: To describe the use of prescribed contraceptives in Northern Ireland 
(NI) and how this varies with a woman’s age, the deprivation in the area in which 
she lives and characteristics of her General Practice (GP). 
Method: A population-based cohort study was conducted including 560,074 
females, aged 12-49 registered with a GP (2010-2016), contributing 3,255,500 
woman-years of follow-up. Dispensed contraceptive prescriptions were linked to 
demographic details. 
Results: A contraceptive prescription was dispensed in 26.2% of woman-years 
with women aged 20-24 most likely to have a contraceptive dispensed (45.7% of 
woman-years). After adjusting for patient and other practice characteristics, 
practices in the least deprived quintile prescribed 6% more contraception than 
those in the most deprived quintile. The combined oral contraceptives (16.6% of 
woman-years) and progesterone only pill (8.0% of woman-years) were the most 
commonly dispensed methods. Patient and practice level characteristics were 
found to be related to the specific contraceptive methods dispensed which also 
changed during the time frame of the study. 
Conclusions: This is the first population-based assessment of contraceptive 
prescription in NI. It is useful for health service planning and to inform broader 
reproductive policy debates. The impact of practice area-based deprivation, 
above that of the woman’s residence, on contraceptive dispensing is a new 
finding that deserves more exploration. 
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Northern Ireland (NI) has been in a unique position in the United Kingdom (UK) as 
until recently abortion was only legal under very limited circumstances [1]. The risk of 
an unintended, potentially unwanted, pregnancy is related to whether or not a woman 
and her partner use any method of contraception and which method they use [2].  It is 
important that contraceptive advice and provision is addressed as part of the policy and 
legal reform now ongoing regarding abortion.   
A 2014 survey by the Family Planning Association found that half of sexually 
active women in NI had had unprotected sex in the previous two years [3]. The most 
commonly used contraceptive methods in NI in the 2014/15 Health Survey were the 
combined oral contraceptive (CoC)/Progestogen only pill (PoP) (34%) and male 
condom (19%) [4]. These methods have some of the highest failure rates [5], due to 
their need for consistent and correct use [6]. Studies of contraceptive use in GB (which 
excludes NI) and Ireland have found that contraceptive use is sociodemographically 
patterned. Women with lower levels of education [7,8], in the low and middle social 
classes and those living in the most disadvantaged areas are less likely to use 
contraception than their more advantaged peers [7]. Contraceptive pill users are younger 
and more likely to be unmarried [8,9] while long-acting reversible contraceptives 
(LARC), which have much lower failure rates than other methods, are used by older 
women [10] and those living in more deprived areas [11,12]. We do not know if, or 
how, contraceptive use in NI varies by age or deprivation. Information on the use of 
contraception in NI would inform the broader reproductive policy debate, make it 
possible to identify any areas of need and aid with health service planning [13]. 
In NI, the Honest Broker Service (HBS) facilitates research using routinely 
collected administrative health datasets. This includes all prescriptions dispensed to the 
NI population since 2010. Through the HBS this project aimed to describe the use of 
prescribed contraceptives in NI and explore how this varies according to a woman’s age 
and the deprivation in the area in which she lives. As the prescriber plays a critical role 
in determining medication use we also explored how the use of prescribed 
contraceptives varies based on characteristics of the woman’s general practice (GP) 
including size of practice, urban/rural location and practice area deprivation.  
Materials and methods 
A population-based cohort study was conducted, through the HBS, using the Enhanced 
Prescribing Database (EPD) and GP Patient Registrations Index 2010-2016. The GP 
Patient Registrations Index records demographic details of patients registered with each 
GP in NI. The EPD includes drugs dispensed in primary care that have been submitted 
to the health service for payment. The information recorded includes substance, date 
dispensed and prescriber. Only prescriptions that are subsequently dispensed and which 
can be liked to a patient are included in the dataset. During the first three months of this 
study patients in NI paid a nominal charge for each prescription dispensed. All 
prescriptions were free from April 2010 [14]. 
The EPD and GP Patient Registrations Index were linked using the patient 
Health and Care Number. The NI Multiple Deprivation Measure 2017 (NIMDM2017) 
quintile for the super output area in which the patient lived on January 1st each year was 
added based on their postcode of residence. The NIMDM2017 is the official measure of 
deprivation in NI and ranks areas based on 7 types or ‘domains’ of deprivation: Income 
Deprivation, Employment Deprivation, Health Deprivation and Disability, Education, 
Skills and Training Deprivation, Access to Services, Living Environment and Crime & 
Disorder [15,16]. For each practice a NIMDM2017 quintile and urban/rural location 
was allocated based on the practice address in 2017. A small number of practices 
(16/359, 4.5%) did not exist in 2017, due to practice closures or mergers, and for these 
practices the urban/rural location, NIMDM2017 quintile and practice size was based on 
1st January 2010 address or practice population.  
All women aged 12-49 years inclusive registered with a GP in NI between 2010 
and 2017 were included. Women entered the cohort at the beginning of the study 
window, on the 1st of January the year they turned 12 or on the 1st January the year 
they first registered with a GP in NI. Women remained in the cohort until the end of the 
study observation period, they reached age 50 or were no longer registered with a GP in 
NI on the 1st January. A change in registered GP did not affect inclusion. Prescribing 
data for each year was included in the dataset only if the woman was registered with a 
GP on the 1st of January that year and on the 1st January in the subsequent year. If a 
woman left the GP register but then returned to it those years where she met the 
inclusion criteria were included.    
The annual percent prevalence of dispensed prescriptions for any, and the 
different methods of contraception, were determined for each calendar year between 
2010 and 2016. Contraceptive prescriptions were recorded under the British National 
Formulary chapter 7, section 3 and chapter 21, section 4. The following types of 
contraceptive were explored: any contraceptive, CoC, PoP, emergency contraceptive 
(EC), injection, implant, intra uterine device/system (IUD/S), transdermal patch, vaginal 
ring and gel. Use of the cap or diaphragm was rare and so was not explored. As a 
woman may use more than one type of contraceptive in any year, she may contribute to 
the prevalence of more than one type of contraceptive in any year. Age was measured 
on the 1st January each year.  
Descriptive statistics were used as appropriate. Comparisons in the prevalence of 
use of any, and the different methods of contraceptive, across patient and GP 
characteristics were made using generalised estimating equations (GEE), with robust 
standard errors based on the sandwich estimator. GEE were used to account for the 
longitudinal nature of the data and clustering of women in GP practices. Age (<16, 16-
19, 20-24, 25-29, 30-34, 35-39, 40-44 and 45+ years), patient address NIMDM2017 
deprivation quintile (1 most deprived - 5 least deprived), practice size (0-2,500; 2,501-
5,000; 5,001-7,500; 7,501-10,000 and 10,000+ registered patients (male and female), 
practice urban/rural location and practice address NIMDM2017 deprivation quintile 
were included as categorical covariates. Categories were combined when necessary, to 
prevent disclosure, if use of a contraceptive was rare. For each analysis, the details of 
the prescribing practice were used, even if this was not the practice the woman was 
registered with on the 1st of January that year.  Data are presented as adjusted 
prevalence rate ratios (aRR) with 95% confidence intervals (CI). The largest category 
was used as the reference group except for year (where 2010 was used) and age (where 
20-24 was used). All analyses were undertaken using Stata version 13 [17]. 
In large database studies, small differences between groups may have very 
narrow and non-overlapping confidence intervals (or “significant” p values) due to the 
number of observations. It is then up to the investigator and the reader to impose their 
own perspective to determine the meaningfulness of differences that can be estimated 
with such high precision in large databases [13]. We chose to limit our interpretation to 
differences of 5% or more.  
The cohort included 560,074 women registered in 359 general practices 2010-
2017. Total follow-up was 3,255,500-woman-years with the mean follow-up of 
individual women 5.8 years. Women were registered with 1-6 GPs during the period 
with practices having 346-5,758 women who met the inclusion criteria registered with 
them.  
Ethics approval  
This study was approved by Ulster University Nursing and Health Research Ethics 
Filter Committee.  
Results 
Between 2010 and 2016, in 26.2% of women years there was a contraceptive 
prescription dispensed, see Figure 1. CoC’s were the most commonly dispensed (16.6% 
of woman-years) followed by the PoP (8.0% of woman-years). Prescribing of other 
contraceptive methods was rarer with the EC dispensed in 1.5% of woman-years, the 
injection in 1.0%, the implant in 0.8%, the IUD/S in 0.6%, patches in 0.3% and the 
vaginal ring and gel dispensed in 0.02% and 0.004% of woman-years respectively. 
Supplemental Table 1 provides more detail on the hormonal content of CoC, PoP and 
IUD/S prescriptions.  
Between 2010 and 2016, dispensing of any contraception remained stable (Table 
1, Figure 2) but the contraceptive methods dispensed varied (Supplemental Table 1, 
Figure 2). After adjustment, there was a 12% reduction in dispensing of the CoC (aRR 
0.88, 95% CI 0.88-0.89), a 6% reduction in the contraceptive injection (aRR 0.94, 95% 
CI 0.92-0.95) and a 5% reduction in the EC (aRR 0.95, 95% CI 0.93-0.96), in 2016 
compared to 2010.  Conversely, there was a 23% increase in dispensing of the PoP 
(aRR 1.23, 95% CI 1.22-1.24), a 12% increase in the contraceptive implant (aRR 1.12, 
95% CI 1.11-1.14) and a 6% increase in the IUD/S (aRR 1.06, 95% CI 1.04-1.09).   
Forty-six percent of women of 20-24 years had a contraceptive dispensed, the 
highest proportion of any age group (see Figure 3, Supplemental Table ). Those 12-16 
were least likely to have a contraceptive dispensed (6.8% of woman-years), followed by 
those 45-49 years old (8.5% of woman-years). Dispensation of the CoC followed a 
similar pattern by age to that for any contraceptive. Dispensation of the PoP showed less 
age variation and was most common in the 35-39 age group. The PoP was the most 
common method of contraception for women over 40. Of the less common methods, 
EC, injection and patches were most common in the 20-24 age group, implant in the 16-
19 age group, IUD/S in the 35-39 age group, vaginal ring in 25-29 age group and gel in 
the 45-49 age group. The age patterning of dispensed contraception was the same after 
adjustment for other patient and GP practice characteristics (Supplemental Table ).  
After adjustment for age and other variables, there was little variation in 
dispensing of any contraception with the deprivation in the area in which a woman lived 
(Table 1). The contraceptive methods dispensed did vary with area deprivation (Table 
2). In the least deprived quintile, EC was dispensed 20% less (aRR 0.80, 95% CI 0.78-
0.81), the injection 12% less (aRR 0.88, 95% CI 0.85-0.90), patch 11% less (aRR 0.89, 
95% CI 0.85-0.94) and PoP 7% less (aRR 0.93, 95% CI 0.92-0.95) compared to the 
most deprived quintile. Conversely there was 5% greater dispensing (aRR 1.05, 95% CI 
1.04-1.07) of the CoC in the least deprived quintile compared to the most deprived 
quintile. 
There was no difference in dispensing of any contraceptive by practice 
urban/rural location (Table 1) but the contraceptive methods dispensed did vary (Error! 
Reference source not found.). After adjustment, rural practices prescribed 20% more 
of the IUD/S (aRR 1.20, 95% CI 1.18-1.21), 15% more of the implant (aRR 1.15, 95% 
CI 1.13-1.16), 9% more of the patch (aRR 1.09, 95% CI 1.06-1.13) and 5% more of the 
CoC (aRR 1.05, 95% CI 1.04-1.05) than urban practices. Rural practices prescribed 6% 
less PoP (aRR 0.94, 95% CI 0.93-0.95) and 7% less EC (aRR 0.93. 95% CI 0.92-0.94) 
than urban practices.  
There was little variation in prescribing of any contraception with practice size 
(Table 1) but the contraceptive method prescribed did vary (Error! Reference source 
not found.). There was a trend for increased prescribing of the CoC and injection with 
decreasing practice size with 7% more CoC (aRR 1.07, 95% CI 1.05-1.08) and 11% 
more of the injection (aRR 1.11, 95% CI 1.07-1.15) prescribed in the smallest practices 
(0-2,500 patients) when compared to practices with 7,501-10,000 patients. The reverse 
of this trend was seen for the IUD/S with smaller practices prescribing 24% less (aRR 
0.76, 95% CI 0.73-0.79) of the IUD/S.  
Those practices in the least deprived areas were 6% more likely to prescribe 
contraception than those in the least deprived areas (aRR 1.06, 95% CI 1.05-1.07) 
(Table 1). After adjustment, practices in the least deprived quintile prescribed 19% less 
of the implant (aRR 0.81, 95% CI 0.79-0.83), 16% less of the transdermal patch (aRR 
0.84, 95% CI 0.79-0.89) and 9% more of the PoP (aRR 1.09, 95% CI 1.08-1.11) than 
those in the most deprived quintile (Error! Reference source not found.). 
Discussion 
Findings and interpretation 
Any prescribed contraception 
This is the first population-based study to explore contraceptive use in NI. Previous 
estimates of contraceptive use were based on small survey samples [4,18,19] and 
limited by inherent reporting (social acceptability and recall) bias [20]. Such bias can 
result in under or over-reporting of sensitive sexual behaviours [13,20,21] but will not 
have affected estimates of prescribed contraceptive use based on dispensed prescription 
records. In keeping with GB and Ireland, we found that just over a quarter of women of 
reproductive age were dispensed prescribed contraceptives in any one year [9,22–24]. 
Those aged 20-24 had the most contraception dispensed, as might be expected from the 
pattern of sexual activity and pregnancy avoidance in this age group [22,23,25]. Those 
less than 16 were least likely to have a contraceptive dispensed, with the CoC and PoP 
the most frequently dispensed. There was no information available on indication for use 
but 40% of hormonal contraceptive use among adolescents in the UK has been reported 
to be for management of menstrual symptoms rather than contraception [26,27]. 
Prior research found that women with lower levels of education [7,8,28,29], 
lower social class [7] and Medicaid recipients [29] were less likely to use contraception. 
We found no relationship between dispensation of prescribed contraception and the 
deprivation in the area in which a woman lived. However, after adjustment for patient 
and other practice characteristics, practices operating in the least deprived quintile 
prescribed 6% more contraception. An effect of practice area-based deprivation on 
contraceptive use has not been reported before. Less dispensing of contraception to 
women attending practices in the more deprived areas increases their risk of unintended 
pregnancy and is of concern.  
Contraceptive method 
In keeping with GB and Ireland, the CoC and PoP were the most commonly dispensed 
methods of contraception [4,9,22,24]. Over the period examined there was a decrease in 
dispensation of the CoC in favour of an increase in the PoP. A similar increase in use of 
the PoP has been seen in Scotland (2005-2009) and is thought to be due to the 
introduction of newer preparations with advantages over earlier versions [22,30]. While 
there appears to be a shift away from oestrogen confining hormonal contraceptives 
these methods do provide non-contraceptive benefits such as improved  menstrual 
symptoms and acne [31]. Indeed, the CoC was still the overwhelmingly preferred 
choice for younger women while those in the older age groups, who may have 
contraindications to the CoC [31,32], were dispensed the PoP. As seen with higher 
educational level in the USA [33–35], women living in areas of less deprivation were 
more likely to have the CoC dispensed and less likely to be dispensed the injection and 
PoP than those living in the more deprived areas. In contrast practices in the less 
deprived areas prescribed more of the PoP supporting the finding that the deprivation in 
the area in which a woman’s GP practice is based contributes to her prescribed 
contraceptive use above that of the area in which she lives.  
Not all use of the EC will have been identified as it can be bought from 
pharmacies without a prescription and is dispensed directly by some sexual health 
clinics. In the NI 2014/15 Health Survey just over a third (36%) of female respondents 
16-54 years old who used EC obtained it form a doctor or nurse at a GP surgery [4]. 
Based on this an estimate of the true use of EC during this period would be about 4%, in 
keeping with the 3.6% seen in the third British National Survey of Sexual Attitudes and 
Lifestyles [36]. A  decrease in dispensed prescriptions for the EC has been seen in 
Scotland (2010-2016) [22] and reflects an increase in sales of the EC from community 
pharmacies [22]. Indeed, there is evidence that use of EC is increasing in GB with the 
greatest increase among women using retail outlets (eight fold increase 2000-2010) 
[36]. This increase in use was greatest in less affluent areas, single women and women 
using less effective methods of contraception [36]. The increase is worrying as EC can 
be considered a marker of risky sexual behaviour, indicating exposure to unprotected 
sex or a failure in contraceptive method [36]. 
Some women will have been obtaining effective contraception from an IUD/S or 
implant inserted in previous years. This explains the lower rate of use of the IUD/S seen 
compared to the 2014/15 Health Survey [4]. While dispensation of LARC methods was 
low, dispensation of the implant and IUD/S has been increasing, as seen in the USA 
[34], GB [22,37] and Ireland [38]. Dispensation of the contraceptive injection has been 
decreasing which may reflect its side effect profile and shorter duration of action, 
relative to other LARC methods [39,40]. There was evidence that the historical 
reluctance to use the IUD/S in nulliparous women [41–43] persists in NI with the IUD/S 
dispensed most to 30-35 year olds while younger women using LARC received the 
injection and implant. Practice size and location also impacted on choice of LARC 
method with smaller practices prescribing more of the contraceptive injection and rural 
practices prescribing more of the IUD/S and implant than urban practices. The National 
Institute of Health and Care Excellence LARC guideline [44] recommends that IUD/S’s 
are only inserted and removed by trained healthcare professionals who insert at least 
one IUD/S a month. Smaller practices will therefore not have enough patients 
requesting an IUD/S to warrant staff training in their insertion [42], or to maintain the 
skill [45]. Sexual health clinics, which are known to prescribe more LARC methods 
[12], tend to be situated in urban areas [46] and urban practices may be referring 
patients to sexual health clinics for LARC [12,22] while rural practices do not have this 
option. It is clear however, that the LARC method a woman receives from general 
practice in NI will depend on her age, the size and urban/rural location of her practice.  
Strength and Weaknesses 
This study does not cover all contraceptive use, as it is restricted to prescribed and 
dispensed methods only. Contraception provided without a prescription in sexual health 
clinics, purchased from pharmacies/shops (e.g. condoms and EC) and sterilisation 
procedures are not included. There will also have been some degree of underestimation 
of contraceptive use, as patient information is not captured for all prescriptions in the 
EPD. However, over the period 89% of prescribed and dispensed items were 
successfully linked to a patient.  
Reliance on dispensed prescription records may however overestimate the actual 
use of prescribed contraceptives as redemption of a prescription does not guarantee the 
contraceptive was actually used [13]. Dispensation information is however a more 
accurate measure of drug exposure than data on prescriptions written as prescriptions 
written by doctors are not always filled by patients [47].  
There was no information on sexual activity, duration and type of relationship 
[23], ethnicity [29,48] or religion [35] which have been shown to be related to 
contraceptive use.  
Open questions and future research 
The finding that practice area-based deprivation, and not that of the area in which a 
woman lives, was related to whether she had any contraception, and the PoP, dispensed 
needs further exploration. The NIMDM2017 is an area-based measure of deprivation 
and it would be of interest to relate contraceptive dispensing to a measure of the 
woman’s individual socioeconomic position. Practice level factors such as distance to 
the nearest sexual health clinic and prescriber characteristics would also be of interest. 
Attitudes on efficacy and safety of different contraceptive methods have for example 
been shown to be related to role (doctor/nurse), gender and age [42]. 
Access to sexual health clinic and pharmacy data would provide further insight 
into provision of contraception in NI, in particular EC and LARC [12]. At present, it is 
not possible to determine if women living in less deprived areas truly use less of the EC 
or if instead, they buy the EC, rather than request a prescription. The same may be true 
for those living in rural communities where pharmacies and sexual health clinics offer 
anonymity compared to general practice.  
Unrealistic expectations, media scares and a lack of awareness of non-
contraceptive benefits can make the adoption of effective birth control methods a 
challenge [49]. A piece of qualitative work exploring awareness of, and attitudes to, 
prescribed contraceptive methods, among women and GPs in NI, would be useful to 
provide insight into the changing use of CoC/PoP and low levels of use of parenteral 
methods of contraception, such as the LARC, patch, ring and gel.  
Conclusion 
This is the first population-based assessment of contraceptive prescription in NI and it 
will be useful to inform reproductive policy debate and health service planning. Patient 
and practice level characteristics were found to be related to the specific contraceptive 
methods dispensed which also changed during the short time frame of the study. The 
new finding that dispensation of contraception was related to practice area-based 
deprivation, and not that of the woman’s residence, deserves more exploration. 
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Table 1 Number, percent of woman-years, crude and adjusted prevalence rate ratios for dispensation of any contraceptive by year, age group, 
woman’s residence area-based deprivation quintile, General Practice urban/rural location, practice size and practice area-based deprivation 
quintile 
 n (%) 
Crude RR  
(95% CI) 
Adjusted RR  
(95% CI) 
Year  
2010 116,478 (25.7) Ref. Ref. 
2011 119,552 (26.2) 1.01 (1.00-1.01) 1.01 (1.01-1.02) 
2012 121,823 (26.5) 1.01 (1.01-1.02) 1.02 (1.02-1.03) 
2013 122,127 (26.3) 1.00 (1.00-1.01) 1.01 (1.01-1.02) 
2014 122,746 (26.2) 1.00 (0.99-1.00) 1.01 (1.01-1.02) 
2015 124,596 (26.3) 1.00 (0.99-1.00) 1.02 (1.01-1.02) 
2016 125,256 (26.1) 0.99 (0.98-0.99) 1.01 (1.00-1.01) 
Age group  
<16 20,822 (6.8) 0.30 (0.30-0.30) 0.3 (0.30-0.30) 
16-19 105,843 (35.6) 0.80 (0.80-0.81) 0.8 (0.80-0.81) 
20-24 181,590 (45.7) Ref. Ref. 
25-29 183,056 (41.5) 0.90 (0.90-0.91) 0.9 (0.90-0.91) 
30-34 147,821 (33.2) 0.72 (0.72-0.73) 0.72 (0.72-0.73) 
35-39 102,629 (23.8) 0.56 (0.55-0.56) 0.56 (0.55-0.56) 
40-44 70,404 (15.3) 0.43 (0.42-0.43) 0.43 (0.42-0.43) 




1 – most deprived  185,050 (27.5) Ref. Ref. 
2 178,988 (26.9) 0.99 (0.98-1.00) 1.00 (0.99-1.01) 
3 172,774 (26.3) 0.97 (0.96-0.98) 0.99 (0.98-1.00) 
4 164,862 (25.3) 0.95 (0.95-0.96) 0.98 (0.97-0.99) 
5 – least deprived 140,539 (24.8) 0.94 (0.94-0.95) 0.98 (0.97-0.99) 
Missing1 10,365 (26.5)  -  - 
Practice urban/rural 
Rural 204,384 (26.5) 1.02 (1.01-1.02) 1.02 (1.01-1.03) 
Urban 648,194 (26.1) Ref. Ref. 
Practice size  
0 to 2,500 34,483 (26.6) 1.02 (1.00-1.03) 1.01 (0.99-1.02) 
2,501 to 5,000 223,637 (27.0) 1.03 (1.03-1.04) 1.03 (1.03-1.04) 
5,001 to 7,500 230,064 (26.2) 1.01 (1.00-1.02) 1.01 (1.00-1.02) 
7,501 to 10,000 228,387 (25.8) Ref. Ref. 
Over 10,000 136,007 (25.5) 1 (0.99-1.01) 0.98 (0.98-0.99) 
Practice address 
NIMDM2017 Quintile 
1 – most deprived  299,366 (25.8) Ref. Ref. 
2 195,391 (26.7) 1.03 (1.02-1.04) 1.05 (1.04-1.05) 
3 139,746 (26.0) 1.01 (1.00-1.02) 1.04 (1.03-1.05) 
4 149,798 (27.0) 1.05 (1.04-1.06) 1.06 (1.05-1.07) 
5 – least deprived 68,277 (25.3) 1.00 (0.99-1.01) 1.06 (1.05-1.07) 
 
                                                 
1 This is the only variable with missing information 
Table 2 Number, percent of woman-years and adjusted prevalence rate ratios for contraceptive methods dispensed across the woman's residence 











Woman’s address NIMDM2017 Quintile 
1 
Most deprived 
2 3 4 
5 
Least deprived Missing 









































































































































































































































































































Emergency contraceptive Contraceptive injection
Contraceptive implant Intra Uterine Device
Transdermal patch Vaginal Ring
Contraceptive gel























































Emergency contraceptive Contraceptive injection
Contraceptive implant Intra Uterine Device
Transdermal patch Vaginal Ring
Contraceptive gel
Figure 1 Percent of woman-years with any and specific, contraceptives dispensed 2010-2016 
Figure 2 Percent of woman-years with any contraception, and specific methods of contraception dispensed each year 2010-2016 
Figure 3 Percent of woman-years in each age group with any, and specific methods of contraception dispensed 2010-2016 
 
Supplemental Online Material 
Supplemental Table 1 Percent of prescriptions for CoC, PoP and IUD/S dispensed 
(2010-2016) by hormonal content 
Contraceptive Percent of prescriptions dispensed 
Combined oral contraceptive  
Estradiol and nomegestrol 0.0 
Ethinylestradiol and desogestrel 6.2 
Ethinylestradiol and drospirenone 19.1 
Ethinylestradiol and gestodene 4.2 
Ethinylestradiol and levonorgestrel 54.4 
Ethinylestradiol and norethisterone 3.1 
Ethinylestradiol and norethisterone acetate 1.8 
Ethinylestradiol and norgestimate 10.9 
Mestranol and norethisterone 0.0 
Estradiol valerate and dienogest 0.2 





Intra Uterine Device/System 
Copper 16.1 
Levonorgestrel 83.9 




2010 2011 2012 2013 2014 2015 2016 
























































































































































































































































































































1.00) 15 (0.0) 
0.92 
(0.83-
1.02) 17 (0.0) 
0.96 
(0.86-
1.07) 21 (0.0) 
0.93 
(0.82-
1.05) 27 (0.0) 0.75 (0.64-0.88) 
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Supplemental Table 4 Number, percent of woman-years and adjusted prevalence rate ratios for contraceptive methods dispensed in rural general 




n (%)  n (%) Adj. RR (95% CI) 
CoC 408,823 (16.5) Ref. 133,005 (17.3) 1.05 (1.04-1.05) 
PoP 204,399 (8.2) Ref. 57,412 (7.5) 0.94 (0.93-0.95) 
Emergency 38,947 (1.6) Ref. 10,197 (1.3) 0.93 (0.92-0.94) 
Injection 23,609 (1.0) Ref. 8,361 (1.1) 1.03 (1.01-1.05) 
Implant 19,126 (0.8) Ref. 7,576 (1.0) 1.15 (1.13-1.16) 
IUD/S 12,343 (0.5) Ref. 6,409 (0.8) 1.20 (1.18-1.21) 
Patch 6,110 (0.3) Ref. 2,102 (0.3) 1.09 (1.06-1.13) 
Vaginal Ring 537 (0.0) Ref. 199 (0.0) 1.05 (0.96-1.14) 
Gel 102 (0.0) Ref. 28 (0.0) 0.94 (0.78-1.12) 
 
  




0 to 2,500 2,501 to 5,000 5,001 to 7,500 7,501 to 10,000 Over 10,000 
n (%) 
Adj. RR 
(95% CI) n (%) 
Adj. RR 
(95% CI) n (%) 
Adj. RR 








































































































































































Supplemental Table 6 Number, percent of women years and adjusted rate ratios for dispensed contraceptive prescriptions by general practice area 
deprivation quintiles 
Contraceptive 
Practice address NIMDM2017 Quintile 
1 
Most deprived 
2 3 4 5 
Least deprived 
n (%)  n (%) 
Adj. RR 
(95% CI) n (%) 
Adj. RR 
(95% CI) n (%) 
Adj. RR 

































































































































Vaginal Ring 256 
(0.0) Ref. 
170 
(0.0) 
1.02 
(0.93-1.12) 
58 
(0.0) 
0.85 
(0.75-0.97) 
163 
(0.0) 
1.12 
(1.02-1.24) 
89 
(0.0) 
1.16 
(1.01-1.33) 
Gel 55 
(0.0) Ref. 
12 
(0.0) 
0.78 
(0.63-0.96) 
19 
(0.0) 
0.92 
(0.73-1.17) 
23 
(0.0) 
0.99 
(0.81-1.22) 
21 
(0.0) 
1.20 
(0.95-1.51) 
 
